CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Multiple sclerosis leads to smoldering inflammation in the central nervous system upheld by proliferating immune cells, including B cells; however, current therapies remain insufficient to target these immune compartments. Here, CD19-targeted CAR-T cell therapy was applied in two patients with multiple sclerosis, showing tolerable safety with promising disease-specific target-cell effects.